Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
AI Summary:
Combined capivasertib and enzalutamide did not significantly improve outcomes from abiraterone pre-treated metastatic castration-resistant prostate cancer (mCRPC).AI Topics:
Background
PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel.
Methods
This double-blind, placebo-controlled, randomized phase 2 trial, recruited men ≥ 18 years with progressing mCRPC and performance status 0–2 from 15 UK centers. Randomized participants (1:1) received enzalutamide (160 mg orally, once daily) with capivasertib (400 mg)/ placebo orally, twice daily on an intermittent (4 days on, 3 days off) schedule. Primary endpoint was composite response rate (RR): RECIST 1.1 objective response, ≥ 50 % PSA decrease from baseline, or circulating tumor cell count conversion (from ≥ 5 at baseline to < 5 cells/7.5 mL). Subgroup analyses by PTENIHC status were pre-planned.
Results
Overall, 100 participants were randomized (50:50); 95 were evaluable for primary endpoint (47:48); median follow-up was 43 months. RR were 9/47 (19.1 %) enzalutamide/capivasertib and 9/48 (18.8 %) enzalutamide/placebo (absolute difference 0.4 % 90 %CI −12.8 to 13.6, p = 0.58), with similar results in the PTENIHC loss subgroup. Irrespective of treatment, OS was significantly worse for PTENIHC loss (10.1 months [95 %CI: 4.6–13.9] vs 14.8 months [95 %CI: 10.8–18]; p = 0.02). Most common treatment-emergent grade ≥ 3 adverse events for the combination were diarrhea (13 % vs 2 %) and fatigue (10 % vs 6 %).
Conclusions
Combined capivasertib/enzalutamide was well tolerated but didn’t significantly improve outcomes from abiraterone pre-treated mCRPC.
Rescigno, Pasquale
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listPorta, Nuria
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listFinneran, Laura
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listRiisnaes, Ruth
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432
See full publications listFigueiredo, Ines
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listCarreira, Suzanne
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listFlohr, Penny
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listMiranda, Susana
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listBertan, Claudia
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listFerreira, Ana
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432
See full publications listCrespo, Mateus
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listRodrigues, Daniel Nava
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listGurel, Bora
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432
See full publications listNobes, Jenny
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listCrabb, Simon
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694
See full publications listMalik, Zafar
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listRalph, Christy
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listMcGovern, Ursula
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listHoskin, Peter
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listJones, Robert
Author
Elyan, Benjamin M.P. and Tan, Beatrix and Lambourg, Emilie and McAllister, David A. and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. and Bell, Samira (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, 18 (5): sfaf084. ISSN 2048-8505
Elyan, Benjamin M.P. and Sullivan, Michael K. and Hedley, James and De La Mata, Nicole and Webster, Angela C. and Venugopal, Balaji and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2: 57. ISSN 2731-9377
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listBirtle, Alison
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listGale, Joanna
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listSankey, Peter
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listJain, Suneil
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listMcLaren, Duncan
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listChadwick, Eliot
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listEspinasse, Aude
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listHall, Emma
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listde Bono, Johann
Author
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listAvailable under License Creative Commons Attribution Non-commercial.
Download (2MB) | Preview
